Notably, gut dysbiosis may contribute to several metabolic disorders involved in sarcopenia and frailty, such as enhanced protein catabolism, pro-inflammatory cytokine production, decreased pro-anabolic mediators’ synthesis and reduced insulin sensitivity, with some of these alterations linked to gut mucosa dysfunction and increased permeability. The gene discussed is INS; the disease is metabolic disease.